Valneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccines
Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.
Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.